Axol Bioscience launches new iPSC-Derived Cells at ISSCR 2016

Axol Bioscience has announced the launch of a new range of human induced pluripotent stem cell (iPSC)-derived cells ahead of their debut at an upcoming industry conference.

The company will attend the International Society for Stem Cell Research (ISSCR) annual conference for 2016 in San Francisco from June 22nd to 25th, allowing it to showcase the benefits of the new product range.

Among them will be new human iPSC-derived atrial cardiomyocytes for the study of atrial fibrillation – anticipated to be a world first – plus endothelial colony forming cells, developed based on expertise from Indiana University.

Also on display will be the company's new axolGEMs (Genetically Edited Models), which were created in partnership with Horizon Discovery. These include cells carrying the Alzheimer's disease-associated microtubule-associated protein TAU mutations P301L, V337M and R406W, as well as the Parkinson's disease-associated leucine-rich repeat kinase 2 mutation G2019S.

Sanj Kumar, chief business officer of Axol Bioscience, said: "We've combined our expertise in reprogramming and neural differentiation with Horizon's broad gene editing platform and extensive experience in developing cell-based disease models to produce one of the world's first commercially available isogenic neural stem cells with disease-relevant mutations."